MediPharm Labs Completes First Shipment to France

Executive Summary

• MediPharm Labs completed its first shipment of pharmaceutical‑grade cannabis products to France, marking entry into a major European medical‑cannabis market.
• The shipment follows a production agreement with an international medicinal‑cannabis organization and demonstrates the Company’s ability to meet stringent EU regulatory standards.
• International medical‑cannabis sales now represent 56% of total revenue, with an 83% YoY growth driven by expanding product portfolios across multiple geographies.

Key Details

• First French Shipment: Completed the inaugural production order and shipment to France under a new production agreement.
• Strategic Significance: Provides a foothold in one of Europe’s fastest‑growing medical‑cannabis markets; projected market size US$187.6 M in 2025, rising to US$213.3 M by 2030 (Statista).
• Regulatory Compliance: Products meet European regulatory standards; the Company leverages its GMP‑certified facilities and multiple international licenses.
• Revenue Impact: International medical‑cannabis now accounts for 56% of MediPharm’s total revenue (Q3 2025); achieved 83% YoY growth in this segment.
• Global Footprint: Products are now shipped to 10 countries, reinforcing the Company’s global distribution network.
• CEO Quote: David Pidduck highlighted the shipment as a milestone that “underscores our ability to establish new pathways to market and deliver pharmaceutical‑grade products that meet stringent European standards.”

Notable Quotes

“MediPharm's completion of our first production order and subsequent shipment to France marks our entry into one of Europe's most promising emerging medical cannabis markets,” – David Pidduck, CEO